After a college student finally found a treatment that worked, the insurance giant decided it wouldn’t pay for the costly drugs. His fight to get coverage exposed the insurer’s hidden procedures for rejecting claims.
by David Armstrong, Patrick Rucker and Maya Miller, Pro Publica
In May 2021, a nurse at UnitedHealthcare called a colleague to share some welcome news about a problem the two had been grappling with for weeks.
United provided the health insurance plan for students at Penn State University. It was a large and potentially lucrative account: lots of young, healthy students paying premiums in, not too many huge medical reimbursements going out.
But one student was costing United a lot of money. Christopher McNaughton suffered from a crippling case of ulcerative colitis — an ailment that caused him to develop severe arthritis, debilitating diarrhea, numbing fatigue and life-threatening blood clots. His medical bills were running nearly $2 million a year.
United had flagged McNaughton’s case as a “high dollar account,” and the company was reviewing whether it needed to keep paying for the expensive cocktail of drugs crafted by a Mayo Clinic specialist that had brought McNaughton’s disease under control after he’d been through years of misery.
Recent Posts
Why Do We Let Zionists Decide What We Can and Can’t Say?
Take Action Now Kraft is a man who appears in the Epstein files, was twice caught on camera with prostitutes, donates heavily to the IDF, and even…
Trump Says He’s Banning CNN, MS NOW, and Politico From the White House
Take Action Now “These outrageous attacks only demonstrate how scared he is of an informed public,” said one press freedom advocate.By Stephen…
Bases Without Names: How Governments Rebrand the U.S. Military Presence
Take Action Now Across Asia, Europe and the Middle East, governments use an expanding vocabulary to describe sites that accommodate U.S. troops,…
Getting Into ‘Good Trouble’ Over Arc de Trump
Take Action Now A retired Army colonel flew in from Hawaii to make sure Trump’s arch doesn’t go up quietlyBy Jonathan Capehart, Substack On the…